Dr. Reddys Laboratories Ltd.

Dr. Reddys Laboratories is currently trading at Rs 3116.80, up by 13.20 points or 0.43% from its previous closing of Rs. 3103.60 on the BSE.

The scrip opened at Rs 3108.00 and has touched a high and low of Rs 3136.00 and Rs. 3050.00 respectively. So far 34076 shares were traded on the counter.

The BSE group 'A' stock of face value Rs 5 has touched a 52 week high of Rs. 4382.95 on 20-Oct-2015 and a 52 week low of Rs. 2750.00 on 21-Jan-2016.

Last one week high and low of the scrip stood at Rs. 3115.00 and Rs. 2883.00 respectively. The current market cap of the company is Rs. 53204.00 crore.

The promoters holding in the company stood at 31.21% while Institutions and Non-Institutions held 53.10% and 15.68% respectively.

Dr. Reddy’s Laboratories has received US Food and Drug Administration (USFDA) tentative approval for Zenavod (doxycycline) Capsules, 40 mg. Zenavod is a tetracycline-class drug indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. Promius Pharma, LLC, the US subsidiary of India’s Dr. Reddy’s Laboratories will be responsible for commercializing Zenavod in the US market.

The approval of the New Drug Application (NDA) is tentative because the USFDA has determined that the drug meets all of the required quality, safety, and efficacy standards for approval, but it is subject to an automatic stay of final approval for up to 30 months pending a patent infringement process under the Drug Price Competition and Patent Term Restoration Act (Hatch Waxman).

Dr. Reddy's Laboratories, is a multinational pharmaceutical company based in Hyderabad, Telangana in India. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas.